Biotech Values

[henrym28]

I don't think that's entirely the case. The drug needs to sell well in order for ENTA to achieve higher tier on its royalties. I think its pretty much expected that the P3 trials will hit their endpoints. Like Dew had said, these are more safety trials. I think with the flood of HCV news we saw this weekend, the market is shifting funds around to other players which can explain the weakness we have been seeing in ENTA as of late.